IOL Chemicals & Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

IOL Chemicals & Pharmaceuticals announced that the 38th Annual General Meeting(AGM) of the company will be held on 22 August 2025.

Powered by Capital Market - Live News

Net profit of IOL Chemicals & Pharmaceuticals rose 13.76% to Rs 31.42 crore in the quarter ended March 2025 as against Rs 27.62 crore during the previous quarter ended March 2024. Sales rose 4.73% to Rs 527.78 crore in the quarter ended March 2025 as against Rs 503.92 crore during the previous quarter ended March 2024.

For the full year,net profit declined 24.82% to Rs 101.07 crore in the year ended March 2025 as against Rs 134.43 crore during the previous year ended March 2024. Sales declined 2.51% to Rs 2079.21 crore in the year ended March 2025 as against Rs 2132.79 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 May 2025.

Powered by Capital Market - Live News

This approval authorizes the company to export Ibuprofen to the Chinese markets. Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID) effective in relieving pain, reducing inflammation, and lowering fever.

IOL Chemicals & Pharmaceuticals is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.

The company?s consolidated net profit declined 11% to Rs 20.53 crore in Q3 FY25 as compared with Rs 23.08 crore in Q3 FY24. Net sales increased 0.6% YoY to Rs 523.30 crore in Q3 FY25.

The scrip declined 1.01% to settle at Rs 65.42 on the BSE.

Powered by Capital Market - Live News